Improving the efficiency of the development of drugs for stroke

David W. Howells*, Emily S. Sena, Victoria O'Collins, Malcolm R. Macleod

*Corresponding author for this work

Research output: Contribution to journalLiterature reviewpeer-review

Abstract / Description of output

The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved. We then propose exemplar strategies which may be helpful, along with some basic economic modelling of what the impact of such strategies might be. This suggests that relatively straightforward measures might reduce the costs of drug development by $5.8?bn or 31%.

Original languageEnglish
Pages (from-to)371-377
Number of pages7
JournalInternational Journal of Stroke
Volume7
Issue number5
DOIs
Publication statusPublished - Jul 2012

Keywords / Materials (for Non-textual outputs)

  • ANIMAL-MODELS
  • translation
  • TISSUE-PLASMINOGEN ACTIVATOR
  • FOCAL CEREBRAL-ISCHEMIA
  • COST
  • EFFICACY
  • NEUROPROTECTION
  • pharmacoecomonics
  • neuroprotection
  • METAANALYSIS

Fingerprint

Dive into the research topics of 'Improving the efficiency of the development of drugs for stroke'. Together they form a unique fingerprint.

Cite this